Serina Therapeutics Appoints Dr. Stephen Brannan to Board

Serina Therapeutics ( (SER) ) has shared an update.

On May 22, 2025, Serina Therapeutics announced the appointment of Dr. Stephen Brannan to its Board of Directors, bringing extensive expertise in neuroscience and neuropsychiatry drug development. Dr. Brannan’s experience, notably his role in the successful development of KarXT at Karuna Therapeutics, aligns with Serina’s focus on long-acting CNS treatments. Concurrently, Remy Gross departed from the Board, transitioning to a consulting role, having contributed significantly to Serina’s growth.

The most recent analyst rating on (SER) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.

Spark’s Take on SER Stock

According to Spark, TipRanks’ AI Analyst, SER is a Underperform.

Serina Therapeutics’ overall stock score is primarily hindered by severe financial challenges, including declining revenue, high liabilities, and negative cash flow. While there is some short-term technical momentum and positive corporate developments, these do not offset the fundamental financial concerns. The valuation remains weak due to negative earnings, contributing to a low overall score.

To see Spark’s full report on SER stock, click here.

More about Serina Therapeutics

Serina Therapeutics is a clinical-stage biotechnology company focused on developing a pipeline of drug product candidates to treat neurological diseases and other indications. Utilizing its proprietary POZ Platform™ technology, Serina aims to enhance the efficacy and safety profile of various modalities, including small molecules, RNA-based therapeutics, and antibody-based drug conjugates. The company is headquartered in Huntsville, Alabama, at the HudsonAlpha Institute of Biotechnology.

Average Trading Volume: 10,074

Technical Sentiment Signal: Sell

Current Market Cap: $56.91M

For a thorough assessment of SER stock, go to TipRanks’ Stock Analysis page.